There are currently 197 clinical trials in Sarasota, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Sarasota Memorial Hospital, Florida Cancer Specialists, GSK Investigational Site and Sarasota Retina Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation
NCT04088071
Recruiting
The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: Sarasota Memorial Hospital, Sarasota, Florida
Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Register for Updates
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NCT05215574
Recruiting
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
02/12/2024
Locations: NGM Clinical Study Site, Sarasota, Florida
Conditions: Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Carcinoma, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
Register for Updates
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Gender:
All
Ages:
All
Trial Updated:
02/12/2024
Locations: Not set, Sarasota, Florida
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Register for Updates
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
NCT04354246
Recruiting
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/10/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
Register for Updates
US Post-Market Surveillance Study of the Surfacer System
NCT05050799
Recruiting
Single arm, observational, multi-center, consecutively enrolling, post-market surveillance study. Treating patients in need of central venous access who have upper body venous occlusions or other conditions that preclude central venous access by conventional methods, and who meet the requirements described in the device labeling.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: Sarasota Memorial Health Care System, Sarasota, Florida
Conditions: Venous Disease
Register for Updates
Study of ARTS-021 in Patients With Advanced Solid Tumors
NCT05867251
Recruiting
This study, the first clinical trial of ARTS-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of ARTS-021 in patients with advanced solid tumors. ARTS-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Solid Tumors
Register for Updates
RESPONDER-HF Trial
NCT05425459
Recruiting
Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization
Gender:
All
Ages:
40 years and above
Trial Updated:
02/05/2024
Locations: Sarasota Memorial Hospital (Intercoastal Medical Group), Sarasota, Florida
Conditions: Heart Failure, Heart Failure, Diastolic
Register for Updates
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
NCT05654532
Recruiting
This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: Identify the recommended dose of AC699 that can be given safely to participants Evaluate the safety profile of AC699 Evaluate the pharmacokinetics of AC699 Evaluate the effectiveness of AC699
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Site 02, Sarasota, Florida
Conditions: Breast Cancer
Register for Updates
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
NCT03775265
Recruiting
This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as gemcitabine, cisplatin, fluorouracil and mitomycin-C, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/03/2024
Locations: Florida Cancer Specialists - Sarasota, Sarasota, Florida +4 locations
Conditions: Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma
Register for Updates
A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee
NCT06000410
Recruiting
This study is being conducted to evaluate the efficacy and safety of ASA compared to placebo in the management of osteoarthritis (OA) symptoms of the knee.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Gulfcoast Research Institute, Sarasota, Florida
Conditions: Knee Osteoarthritis
Register for Updates
A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors
NCT05821777
Recruiting
The purpose of this study is to assess safety, tolerability, and preliminary activity of LB101 monotherapy in participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: Sarah Cannon Research Institute at Florida Cancer Specialists, Sarasota, Florida
Conditions: Advanced Solid Tumor
Register for Updates
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Covenant Metabolic Specialists LLC - Sarasota, Sarasota, Florida
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates